Ad
related to: systemic lupus erythematosus therapeutic procedures in childrenContact our dedicated support team for help e-prescribing. Complete the patient start form to begin.
- Safety & Efficacy Data
View safety and efficacy profile
assessed in clinical trials.
- Important Safety Info
Visit Official HCP Website
for full product information.
- Starting Treatment
Get official info and learn how to
initiate treatment. See MOA info.
- Lupus Nephritis Treatment
Info on an oral treatment option.
Learn more about treating LN.
- Safety & Efficacy Data
Search results
Results from the WOW.Com Content Network
Childhood-onset systemic lupus erythematosus (i.e., cSLE), also termed juvenile-onset systemic lupus erythematosus, juvenile systemic lupus erythematosus, and pediatric systemic lupus erythematosus, is a form of the chronic inflammatory and autoimmune disease, systemic lupus erythematosus (i.e., SLE), that develops in individuals up to 18 years old. [1]
Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. [1] Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs.
Autoimmune optic neuropathy (AON), sometimes called autoimmune optic neuritis, may be a forme fruste of systemic lupus erythematosus (SLE) associated optic neuropathy.AON is more than the presence of any optic neuritis in a patient with an autoimmune process, as it describes a relatively specific clinical syndrome.
Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [ 1 ]
Fast Track designation is designed to expedite clinical development and regulatory review timelines. Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. [medical citation needed]
Neuropsychiatric systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus. SLE is a disease in which the immune system attacks the body's own cells and tissues. It can affect various organs or systems of the body.
Systemic lupus erythematosus is the most common form of lupus and is a condition in which the immune system attacks healthy bodily tissue causing wide-spread inflammation and tissue damage across many organ systems. Hypomethylation is observed across the epigenome in those with systemic lupus.
Ad
related to: systemic lupus erythematosus therapeutic procedures in children